Drug-Eluting Stents Versus Bare-Metal Stents in Patients With End-Stage Renal Disease

In patients with end-stage renal disease, the use of drug-eluting stents could significantly reduce the rates of mortality, myocardial infarction and major adverse cardiac events without increased risk of stent thrombosis. It poses imperative demands for future prospective randomized studies to define the optimal stent choice in this high-risk population.